The results of the study indicate that olanzapine, which is associated with weight gain, causes a significant increase in postprandial insulin, glucagon-like peptide 1 (GLP-1), and glucagon levels, which co-occurs with insulin resistance compared to placebo. The gene discussed is GCG; the disease is Insulin resistance.